Janjigian, Y. Y., Al-Batran, S., Wainberg, Z. A., Muro, K., Molena, D., Cutsem, E. V., Hyung, W. J., Wyrwicz, L., Oh, D., Omori, T., Moehler, M. H., Garrido, M., Oliveira, S. S., Liberman, M., Oliden, V. C., Smyth, E. C., Serrano, O., Heilbron, E., Negro, A., Tabernero, J. (2025). Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.17_suppl.lba5